NTRK2 and medulloblastoma: Furthermore, ANA-12 has been used to target NTRK2 in studies of medulloblastoma (Thomaz et al., 2019), gliomas (Pinheiro et al., 2017), leukemia (Polakowski et al., 2014), lung adenocarcinoma metastasis (Sinkevicius et al., 2014), lymphoid tissue neovascularization (Dalton et al., 2015) and endometriosis (Lee et al., 2021), etc. Experimental validation was performed on the hub gene.